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ABSTRACT

The immune system has been implicated in recovery and muscle regeneration following
exercise. In response to muscle damage, the immune system responds with an increase in
circulating pro-inflammatory cytokines with the goal of recruiting leukocytes to the damaged
area. Tumor Necrosis Factor-alpha (TNF-α), in particular, has been shown to be implicated in
both muscle regeneration and muscle wasting. However, it remains unclear whether TNF-α is
responsible for the age-related losses in muscle size and function. Also, due to the high clearance
rate of TNF-α from circulation, analyzing the circulating levels of soluble TNF-α receptors 1 and
2 (STNFR1 and STNFR2) may provide a better indication of inflammatory events. Therefore,
the purpose of this study was to compare changes in circulating levels of TNF-α, STNFR1, and
STNFR2 following an acute muscle damaging intervention in young age (YA) and middle-aged
(MA) males. Recreationally active young (YA; N=9, 21.8 ± 2.2 y, 179.5 ± 4.9 cm, 91.2 ± 12.2
kg, 21.8 ± 4.3% BF) and middle-aged (MA; N=10, 47.0 ± 4.4 y, 176.8 ± 7.6 cm; 96.0 ± 21.5 kg,
25.4 ± 5.3% BF) males completed an acute muscle damaging protocol (MDP). Blood samples
were obtained at baseline (BL), immediately (IP), 30 minutes (30P), 60 minutes (60P), 120
minutes (120P), 24 hours (24H), and 48 hours (48H) post-MDP. Lower body performance was
analyzed via isokinetic dynamometer at BL, IP, 120P, 24H, and 48H. No significant group x
time interactions or main group effects were observed for TNF-α, STNFR1, STNFR2 or any
marker of muscle damage. When collapsed across groups, plasma lactate was significantly
elevated at IP (p < 0.001) and 30P (p = 0.003); serum myoglobin was increased at 30P (p =
0.002), 60P (p = 0.001), and 120P (p = 0.007); creatine kinase was elevated at 24H (p = 0.001)
iii

and 48H (p = 0.005). Plasma concentrations of TNF-α were unchanged following MDP. With
both groups combined, serum STNFR1 was decreased at 30P (p = 0.001) and increased at 48H (p
= 0.028). Serum STNFR2 was decreased at 30P (p = 0.008), 60P (p = 0.003), and 120P (p =
0.002). The results of this study indicate that the TNF-α and STNFRs response to exercise is
similar between young and middle-aged males. Measuring STNFRs may be a more appropriate
method of assessing the acute inflammatory response to muscle damage. In addition, an acute
bout of exercise may attenuate ectodomain shedding of TNFR1 and TNFR2.
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CHAPTER ONE: INTRODUCTION

The term “sarcopenia” was initially used to describe the age-related loss of muscle mass.
More recent definitions include measures of muscle mass, strength, and physical performance;
all of which decline with age (Dodds, Roberts, Cooper, & Sayer, 2015). The number of people
affected by sarcopenia is currently estimated at 50 million and is projected to increase to more
than 200 million by 2050 (Cruz-Jentoft et al., 2010). The prevalence is reported to be 5-13% in
individuals between the ages of 60 and 70 years old and 11-50% in individuals over the age of 80
(Cruz-Jentoft et al., 2010; Morley, 2008). As sarcopenia progresses, it may lead to disability and
frailty, which in turn may lead to a loss of independence (Roubenoff, 2001). The significance of
sarcopenia is evident in findings that show an association between weaker grip strength and
higher risk of all-cause mortality in middle- and older-aged individuals (Cooper, Kuh, & Hardy,
2010). Age-associated decrements in both power and strength have been shown to begin as early
as age 40 and continue to decline with increasing age (Metter, Conwit, Tobin, & Fozard, 1997).
Although impaired movement is often the cynosure of sarcopenia, decreased muscle mass may
also disrupt glucose regulation, hormone production, and communication between cells, which
may lead to comorbidities and/or increased risk of mortality (Buford et al., 2010).
The immune system has been implicated in recovery and muscle regeneration following
exercise (Hawke & Garry, 2001; Paulsen, Mikkelsen, Raastad, & Peake, 2012). When exercised
muscle fibers are damaged, an inflammatory response is initiated with the goal of removing
cellular debris and recruiting cells that aid in repair (Clarkson & Hubal, 2002). This process
includes the recruitment and migration of immune cells, and muscle cell precursors in response
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to cytokines and chemokines (Cannon & Pierre, 1998). These cell messengers are released by
nearly all nucleated cells and can mediate both pro- and anti-inflammatory responses (Cannon &
Pierre, 1998; Hirose et al., 2004; Pedersen & Hoffman-Goetz, 2000). Tumor necrosis factoralpha (TNF-α) in particular is known to play a key role in controlling this response.
Chronic exposure to excessive TNF-α has been shown to result in whole-body protein
decrements, which may adversely affect muscle function and possibly contribute to the onset of
sarcopenia (Brüünsgaard & Pedersen, 2003; Tracey & Cerami, 1992). Consistent with this,
increased basal concentrations of TNF-α have been reported in older adults compared to their
younger counterparts (Bruunsgaard et al., 1999; Woods, Wilund, Martin, & Kistler, 2012).
Chronically elevated levels of TNF-α have been shown to disrupt myofibrillar differentiation,
stimulate catabolism, and induce apoptosis through the death domain receptors in muscle cells
(Krabbe, Pedersen, & Bruunsgaard, 2004; Roubenoff, 2003). Furthermore, evidence suggests
that elevated levels of TNF-α are inversely related to skeletal muscle protein synthesis, and may
cause increased basal energy expenditure, as well as loss of bone and muscle mass (Greiwe,
Cheng, Rubin, Yarasheski, & Semenkovich, 2001; Krabbe et al., 2004).
In contrast, the acute production of low concentrations of endogenous TNF-α appears to
be beneficial for the coordination of tissue remodeling and recovery from muscle damage
(Tracey & Cerami, 1992). Administration of low levels of recombinant TNF-α in vitro has been
shown to play a role in the activation and proliferation of satellite cells (Li, 2003). Consistent
with this, eliminating the effects of TNF-α in mice, either through double-knockout of its
receptors or through neutralizing antibodies has been shown to negatively affect strength
recovery following muscle damage when compared to wild-type mice (Warren et al., 2002). The
acute production and autocrine signaling of TNF-α in macrophages following muscle damage
2

can trigger the release of growth factors that promote tissue remodeling (Noble, Lake, Henson, &
Riches, 1993). This may explain the observed findings of a number of investigative groups
whereby TNF-α expression in skeletal muscle and/or plasma is increased following resistance
exercise (Buford, Cooke, & Willoughby, 2009; Townsend et al., 2013; Wells et al., 2016).
Notwithstanding, research comparing circulating levels of TNF-α between middle-aged adults
and younger adults is lacking. Limited evidence suggests that chronic elevations in basal TNF-α
may contribute to the development of sarcopenia. However, evidence also suggests that there
may be an age-associated blunting of the TNF-α response to acute exercise in older adults
(Hamada, Vannier, Sacheck, Witsell, & Roubenoff, 2005). This blunted TNF-α response may
lead to an age-associated decrement in strength recovery following an acute bout of resistance
exercise. Whether differences in basal TNF-α concentrations and/or the acute TNF-α response to
exercise become evident with advancement of chronological age is currently unclear.
TNF-α elicits its effects through two transmembrane tumor necrosis factor receptor
(TNFR) molecules, TNFR1 and TNFR2 (Fiers, 1991). Ectodomain shedding of both of these
receptors leads to release of their soluble forms (STNFR1 and STNFR2) into circulation
(Buckley et al., 2005; Giai et al., 2013; Wallach et al., 1991), which can be found in small
amounts in the serum and urine of healthy individuals (Nicod, 1993; Wallach et al., 1991).
Similar to its ligand, the release of STNFRs appears to have several functions. A number of
reports suggest that the ectodomains of TNFRs are shed to inhibit TNF-α signaling, protecting
the cells from the harmful effects of excessive TNF-α (Aderka, 1996; Wallach et al., 1991). In
contrast, others suggest that STNFRs serve to bind and sequester TNF-α, protecting it from
denaturation and prolonging its effects (Aderka, Engelmann, Maor, Brakebusch, & Wallach,
1992; van Deuren, 1994). Despite some research indicating that serum levels of STNFR1 and
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STNFR2 are elevated in conjunction with elevated levels of TNF-α following strenuous exercise,
research observing the effects of muscle damage on circulating levels of STNFR1 and STNFR2
are lacking (Ostrowski, Rohde, Asp, Schjerling, & Pedersen, 1999).
To our knowledge, no study to date has investigated the TNF-α and STNFRs responses to
muscle damage in middle-aged adults compared to their younger counterparts. Therefore, the
purpose of this study was to compare changes in circulating levels of TNF-α and STNFRs
following an acute muscle damaging intervention in young and middle-aged males. The
relationship between circulating levels of TNF-α, STNFR1, and STNFR2 and isokinetic strength
following muscle damage was also examined. A secondary purpose was to examine the
relationship between basal circulating levels of TNF-α, STNFR1 and STNFR2 and muscle size
and function in middle-aged adults to determine if TNF-α levels may indicate early signs of the
age-associated loss of muscle mass and strength.
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CHAPTER TWO: LITERATURE REVIEW

Skeletal muscle is capable of adapting to and recovering from a wide variety of
physiological challenges including severe tissue injury (Hawke & Garry, 2001). Both direct and
indirect evidence indicates that arduous, unaccustomed exercise leads to damage within muscle
tissue, which provides a stimulus for repair and growth (Clarkson, Nosaka, & Braun, 1992;
Hawke & Garry, 2001). The severity of the damage depends on the intensity, duration and type
of exercise (Malm, 2001). Eccentric contractions, where muscles contract while lengthening, is
known to cause more damage and inflammation than concentric exercise of the same intensity
and duration (Friden, Sjöström, & Ekblom, 1983; Malm, 2001). Muscle damage is characterized
by increased serum concentrations of creatine kinase and myoglobin, alterations in ultrastructural
integrity, inflammation, increased proteolytic enzymes, and ultimately a decrease in force
production (Brancaccio, Lippi, & Maffulli, 2010; Sorichter et al., 1997; Stupka, Tarnopolsky,
Yardley, & Phillips, 2001; Warren, Lowe, & Armstrong, 1999). The initial response to skeletal
muscle damage involves activation of the innate immune system (Tidball & Villalta, 2010). The
primary role of the innate immune response is to clear cellular debris in preparation for
regeneration and repair of damaged muscle fibers, blood vessels, nerve fibers, and the
extracellular matrix (Clarkson & Hubal, 2002). The acute inflammatory response to exerciseinduced muscle damage (EIMD) is similar to the response to infection (Tidball, 1995).
Neutrophils are the first responders and begin to appear within 2 hours of muscle damage.
Neutrophil infiltration is followed by the invasion of phagocytic macrophages (Aderem &
Underhill, 1999; Tidball & Villalta, 2010; Wynn & Barron, 2010). Neutrophils and macrophages
contribute to the lysis of damaged muscle tissue by releasing reactive oxygen and nitrogen
5

species (Nguyen & Tidball, 2003a; Nguyen & Tidball, 2003b). However, the functions of
macrophages after EIMD go beyond phagocytosis of cellular debris, as evidence suggests that
they remain present during the regenerative phase of muscle damage (Saclier, Cuvellier,
Magnan, Mounier, & Chazaud, 2013).
Muscle Repair
Adult human skeletal muscle is a structurally unique tissue containing highly specialized
fibers with the capacity to adapt to physiological demands such as postnatal growth, training, and
damage (Hawke & Garry, 2001; Zammit & Beauchamp, 2001). These specialized functions are
possible through terminal differentiation, which involves withdrawal from the cell cycle and
establishment of a specific configuration of expressed genes that determine cellular function and
identity within muscle (Zammit & Beauchamp, 2001). This high degree of specialization comes
at the cost of the lost ability to proliferate. Therefore, muscle growth and repair depends on the
persistence of a small population of cells located between the sarcolemma and the basal lamina,
termed satellite cells (Mauro, 1961). These cells are undifferentiated myogenic precursors with
the ability to re-enter the cell cycle in order to generate new muscle fibers and daughter cells that
become new satellite cells (Kadi et al., 2005). Because skeletal muscle is a post-mitotic tissue
containing hundreds of terminally differentiated nuclei per fiber (myonuclei), satellite cells also
provide the only source of new myonuclei (Martin & Lewis, 2012). Satellite cells are mitotically
quiescent, but are activated in response to increased workload, EIMD, exercise-induced release
of inflammatory signals, and/or release of growth factors after exercise (Kadi et al., 2005). Once
activated, satellite cells proliferate and either fuse to existing muscle fibers to provide new
myonuclei or return to quiescence (Martin & Lewis, 2012). In vitro research has shown that
macrophages release growth factors that stimulate the proliferation and differentiation of satellite
6

cells and myoblasts (Cantini et al., 1994; Cantini & Carraro, 1995). The importance of
macrophages is highlighted by the fact that muscle regeneration cannot occur in the absence of
macrophages (Lescaudron et al., 1999).Satellite cell proliferation and fusion is dependent on the
release of growth factors, such as insulin-like growth factor (IGF)-1, which is upregulated in
response to EIMD (Hawke & Garry, 2001). In response to these growth factors released from the
injured muscle fibers and activated macrophages, satellite cells proliferate and then withdraw
from the cell cycle and self-renew or form new centrally nucleated myotubes approximately 5
days after injury (Hawke & Garry, 2001). The process of myofiber damage, leukocyte
infiltration, and satellite cell activation is depicted in Figure 1.
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Figure 1: Leukocyte infiltration and satellite cell activation following muscle damage
(a)Exercise-induced muscle damage (EIMD) occurs. (b) Neutrophils and macrophages
infiltrate the damaged area where they remove cellular debris and attract satellite cells to
proliferate.
Adapted from: Vierck et al. (2000).

Cytokines
The process of muscle hypertrophy is highly dependent on the activity of cytokines.
Cytokines are small messaging proteins that influence the survival, proliferation, differentiation
and function of immune cells (Calle & Fernandez, 2010). They can be secreted by many
nucleated cells including: neutrophils, activated macrophages, damaged myofibers and
endothelial cells (Cannon & Pierre, 1998). Cytokines usually act in a paracrine or autocrine

8

manner at very low concentrations and elicit their effect through high affinity receptors on the
surface of target cells (Nicod, 1993). Additionally, cytokines can stimulate further production of
cytokines and/or hormones from the target cells (Cannon & Pierre, 1998). Though cytokines
often exhibit both pro- and anti-inflammatory tendencies, certain cytokines are known to induce
a primarily pro-inflammatory response. The pro-inflammatory cytokines include interleukin (IL)1ß and TNF-α, which are known to promote inflammation following EIMD (Hirose et al., 2004).
While TNF-α and IL-1ß are released following strenuous exercise, this release is
counterbalanced with the release of IL-6, IL-1 receptor antagonist (IL-1ra) and soluble TNF-α
receptors which inhibit the previously mentioned pro-inflammatory effects (Pedersen &
Hoffman-Goetz, 2000). Despite TNF-α’s close relationship to IL-1ß and other cytokines, this
review will focus on TNF-α and its receptors.
TNF-α
TNF-α was discovered in vitro as an endotoxin-inducible substance produced by
macrophages that caused necrosis of tumors in mice (Carswell et al., 1975). In other words,
when the endotoxin was administered to the mice, macrophages produced TNF-α which worked
as a toxin against the tumor. Further research on TNF-α showed that the administration of either
recombinant TNF-α or lipopolysaccharide (LPS), a TNF-α-inducer, controlled tumor growth
both in vitro and in vivo (Haranaka, Satomi, & Sakurai, 1984; Matthews, 1979; Prince,
Anderson, & Tomasi, 1982; Sedger & McDermott, 2014). However, human clinical trials were
not successful. The hopes of TNF-α being the cure for cancer were dismissed, as the results of
human clinical trials showed that TNF-α treatment led to adverse effects and a lack of
therapeutic benefit for tumor necrosis (Roberts, Zhou, Diaz, & Holdhoff, 2011; Sedger &
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McDermott, 2014). Despite the lack of success of TNF-α as a treatment for cancer, TNF-α is
now known to have pleiotropic functions (Tracey & Cerami, 1992).
TNF-α exists as a membrane-bound precursor (mTNF-α) with a molecular mass of 26
kDa ,expressed on the surface of activated monocytes/macrophages, natural killer cells, and T
cells, but also on non-immune cells such as endothelial cells and fibroblasts (Moss et al., 1997;
Sedger & McDermott, 2014). The 17 kDa soluble form of TNF-α is produced in response to the
cleavage of mTNF-α from the cell membrane via the metalloprotease, TNF-α converting enzyme
(TACE) (Black et al., 1997; Moss et al., 1997). Though mTNF-α is considered to be a precursor
to TNF-α, there is evidence suggesting that mTNF-α can also mediate signaling through TNF-α
receptors via cell-to-cell contact (Grell et al., 1995; Perez et al., 1990). In addition to serving as
an activating ligand on surface receptors, some studies have revealed that mTNF-α also acts as a
receptor that transmits reverse signals into the effector cells when activated with an antibody
against TNF-α or with soluble TNF-α receptors (Eissner, Kolch, & Scheurich, 2004). TACE,
also called a disintegrin and metalloproteinase (ADAM)-17, is a cell-surface protein with
proteolytic properties expressed on various tissues including brain, heart, and skeletal muscle
(Black et al., 1997; Gooz, 2010).Once TNF-α is released from the cell membrane, it can then
bind to a receptor on the same cell; it can bind to receptors on neighboring cells; it can reach
distant cells in the same tissue; or it may enter the bloodstream (Gooz, 2010). When TACE is not
present, there is an 89-90% reduction in TNF-α release and a corresponding increase in mTNF-α
(Black et al., 1997). TACE cleaves mTNF-α as well as TNF-α receptors in order to regulate
cellular signaling and affect cell behavior (Figure 2). The cleavage of TNF-α receptors is
discussed later on this review.
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Figure 2: Shedding of mTNF-α and/or TNF-α receptor
Once the transmembrane precursor of Tumor Necrosis Factor-α (mTNF-α) is cleaved by
TNF-α converting enzyme (TACE), it becomes a soluble TNF-α molecule than can then
bind to its receptor on the same cell (autocrine signaling), neighboring cells (paracrine
signaling), or enter the blood stream and bind to receptors on distant cells and initiate
downstream signaling events (endocrine signaling). TACE can also cleave TNF-α
receptors from the cell membrane, turning them into soluble TNF-α receptors which can
then bind to TNF-α (sequestration; discussed later in this review).
Adapted from: Blobel (2005).

Functions of TNF-α
TNF-α is considered to be one of the most multifunctional, or pleiotropic, cytokines
(Rothe, Gehr, Loetscher, & Lesslauer, 1992). Its functions range from mediating shock in sepsis
to necrosis of tumors (Tracey & Cerami, 1992). Binding of TNF-α to a wide variety of cell types
activates signaling pathways that regulate several different processes such as apoptosis,
inflammation, immunity, metabolism, and disease (Chen & Goeddel, 2002; Liu, 2005).
Depending on the cellular context and its concentration in the tissues, the net effect of TNF-α
may be beneficial or injurious to the host. TNF-α has been shown to be one of the most abundant
early mediators during inflammation (Parameswaran & Patial, 2010). It is considered to be a
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“master regulator” of pro-inflammatory cytokine production due to its pivotal role in mediating
the production of a pro-inflammatory cytokine cascade following trauma, infection, or exposure
to bacterial-derived LPS (Parameswaran & Patial, 2010). TNF-α has also been shown to have
effects on the vascular endothelium and circulating leukocytes. These effects include an
elevation in the gene expression of adhesion molecules and chemokines by endothelial cells, and
increased recruitment and adhesion of neutrophils and monocytes following muscle damage
(Bevilacqua, Pober, Mendrick, Cotran, & Gimbrone, 1987; Peterson, Feeback, Baas, & Pizza,
2006; Weller, Isenmann, & Vestweber, 1992). Evidence suggests that chronic elevations of TNFα may inhibit the removal of apoptotic neutrophils by monocyte-derived macrophages
(Michlewska, Dransfield, Megson, & Rossi, 2009). Because apoptosis of neutrophils and
subsequent removal by macrophages is a key step in the resolution of inflammation, this effect of
chronically elevated TNF-α may contribute to the tissue damage associated with chronic
inflammatory conditions. In addition to the recruitment and adherence of neutrophils, TNF-α has
also been shown to prime neutrophils for enhanced phagocytosis and respiratory burst activity by
triggering the release of reactive oxygen species and inducing degranulation (Atkinson, Marasco,
Lopez, & Vadas, 1988; Nathan et al., 1989; Richter, Andersson, & Olsson, 1989; Shalaby et al.,
1985). TNF-α has been shown to play an important role in the proliferation, apoptosis, and
differentiation of macrophages (Parameswaran & Patial, 2010). Lombardo and colleagues (2007)
demonstrated that long-term survival of macrophages requires autocrine signaling by TNF-α.
Increased levels of circulating and/or muscle TNF-α have been linked to age-related muscle loss,
insulin resistance, and increased mortality (Bruunsgaard, Andersen-Ranberg, Hjelmborg,
Pedersen, & Jeune, 2003; Greiwe et al., 2001; Paolisso et al., 1998). TNF-α also modulates
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growth and differentiation in many cell types (Li & Reid, 2001; Warren et al., 2002). Moreover,
evidence suggests that TNF-α plays a large role in skeletal muscle metabolism.
TNF-α and muscle regeneration
TNF-α released following muscle damage has an important role in muscle repair (Li &
Schwartz, 2001; Li, 2003; Warren et al., 2002). In addition to activated macrophages, muscle
fibers have been shown to synthesize TNF-α, which perhaps functions in an autocrine fashion on
the muscle cell itself (Saghizadeh, Ong, Garvey, Henry, & Kern, 1996). Mechanical damage to
muscle causes a disruption in extracellular matrix, causing hyaluronate to leak out of the cell and
activate the production of TNF-α and IL-1ß in macrophages. Evidence suggests that the binding
of hyaluronate to the cell surface adhesion molecule CD44 on macrophages causes the
production of TNF-α, which then causes the release of macrophage-derived IGF-1 via autocrine
signaling of TNF-α (Noble et al., 1993). Noble et al (1993) noted that macrophage release of
IGF-1 following hyaluronic acid stimulation of CD44 requires TNF-α production, since IGF-1
protein synthesis was inhibited when TNF-α signaling was prevented. Further, TNF-α may also
recruit fibroblasts to proliferate and/or to synthesize extracellular matrix molecules (such as
collagen), in order to repair and regenerate damaged connective tissue (Cannon & Pierre, 1998;
Kovacs & DiPietro, 1994). Consequently, TNF-α appears to play a significant role in
maintaining the integrity of skeletal muscle tissue.
The presence of TNF-α during muscle regeneration has been shown in several models.
Collins & Grounds (2001) showed that TNF-α was highly expressed in injured and necrotic
muscle fibers of mice. Uninjured skeletal muscle did not have an increased expression of TNF-α,
indicating that significant muscle damage must occur in order for TNF-α to be present.
Additionally, infiltrating macrophages, neutrophils, and activated mast cells were shown to be
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sources of TNF-α during injury. Normal muscle regeneration has been demonstrated in mice
lacking TNF-α (TNF-α-/-), indicating that other cytokines, perhaps IL-12, IL-1ß, and/or IL-6 may
effectively and efficiently take over TNF-α’s role in its complete absence. That is, the absence of
TNF-α had no effect on the timing and extent of inflammation and muscle repair. This
compensatory upregulation of other cytokines is not apparent when TNF-α is present, indicating
that only mice completely lacking TNF-α may regenerate muscle through other cell mediators
when TNF-α is not involved (Collins & Grounds, 2001). Additionally, TNF-α receptor signaling
has been shown in the absence of TNF-α ligand binding, adding another possible explanation to
the normal muscle regeneration seen in TNF-α-/- mice (Collins & Grounds, 2001; Engelmann et
al., 1990). The investigators also observed thin, weak skin as well as poor capillary integrity in
TNF-α-/-mice, indicating TNF-α also has a role in skin healing, connective tissue regeneration,
and angiogenesis (Collins & Grounds, 2001). Another study showed that traumatic freezeinduced skeletal muscle injury in adult mice was accompanied by an increase in TNF-α
expression with a single peak at 24 h post-injury and a gradual reduction over 3-7 days postinjury (Warren et al., 2002). The increase in TNF-α coincided with the infiltration of activated
monocytes and macrophages, highlighting TNF-α’s role in regulating monocytes/macrophages
during muscle damage. However, blocking the effects of TNF-α, either by double knockout of
both TNF receptors (TNFR-DKO) or by neutralizing antibodies to TNF-α, did not significantly
affect inflammatory cell infiltration; demonstrating the possible compensatory roles of other
cytokines in leukocyte recruitment. Nevertheless, mice lacking the TNF-α receptors displayed
16-19% lower muscle strength than the wild-type mice despite similar body masses prior to
muscle injury. In this study, no significant differences in strength recovery were noted between
wild-type mice and TNF-deficient mice at day 5 post-injury. However, at 13 days post-injury,
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strength for the wild-type mice had recovered considerably and was only 13% lower than preinjury, while strength for the TNF-DKO mice and the TNF-α antibody-treated mice had not yet
recovered and was still 27-31% lower than pre-injury (Warren et al., 2002). These results are in
agreement with the findings of Spencer and colleagues (2000), who found that TNF- and
dystrophin-deficient (TNF-/mdx) mice weighed significantly less than mice that were only
dystrophin-deficient (TNF+/mdx) at 8 weeks of age. Furthermore, the quadriceps and diaphragm
muscles of TNF-/mdx were significantly smaller than that of the TNF+/mdx mice at 8 weeks of
age, indicating TNF-α’s role in skeletal muscle development (Spencer et al., 2000; Warren et al.,
2002). Zádor and colleagues (2001) found that mRNA and protein levels of TNF-α were
dramatically increased following toxin-induced necrosis in the soleus and extensor digitorum
longus of rats. This increase was seen at the onset of necrosis and invasion of macrophages,
while a smaller increase in TNF-α was also seen during regeneration phase of the muscle. This
finding further indicates the potential role of TNF-α in the regeneration process, though the
investigators also suggested that the second wave of TNF-α may be due to newly formed muscle
fibers that failed to fully develop and therefore became apoptotic (Zádor et al., 2001).
The TNF-α response to exercise has also been observed in humans. Buford and
colleagues (2009) observed the effects of an acute bout of resistance exercise consisting of 3 sets
of 10 repetitions on machine squat, leg press, and leg extension at 80% of one repetition
maximum (1-RM) on several inflammatory-related genes in post-menopausal women. The
investigators observed a significant up-regulation in mRNA content for TNF-α and IL-1ß in
muscle tissue of the vastus lateralis 3-hours post-exercise. They also examined serum levels of
TNF-α and IL-1ß at baseline as well as 3, 42, and 48 h post-exercise and found no significant
changes between time-points. The investigators noted a limitation in the study was that they did
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not measure protein expression of the markers in the muscle, therefore the posttranscriptional
events that took place following exercise were not accounted for in these findings. Additionally,
the study did not include any measurements of muscle damage, therefore it is not known whether
the protocol they used induced muscle damage or if the results indicate a response to muscle
contraction rather than muscle injury (Buford et al., 2009). Hamada et al. (2005) found that an
acute bout of eccentric exercise (downhill running) elevated gene expression of TNF-α and IL-1ß
in the vastus lateralis of physically active young (age 23-35 years) and old (age 66-78 years) men
during the repair phase of muscle damage (72 h post-exercise). These increases correlated
strongly with the increased infiltration of leukocytes. TNF-α mRNA increased 2.8 and 1.8-fold
in the young and old group, respectively. The investigators mentioned that the eccentric protocol
did elicit muscle damage and systemic inflammation, determined by elevated levels of
circulating creatine kinase and C-reactive protein, though the data was not shown (Hamada et al.,
2005). The difference in the response to muscle damage between young and older adults will be
discussed in more detail later in this review.
Other studies have reported increased TNF-α in circulation following resistance training
or prolonged exercise. Townsend and colleagues (2013) found that circulating TNF-α was
significantly elevated in young (age 22.3 ± 2.4 years) resistance-trained males immediately after
an intense lower-body, muscle-damaging resistance training protocol. However, no significant
increases were seen 30 minutes, 24 hours, or 48 hours post-exercise. Also, the significant
increase in serum TNF-α was blunted with the consumption of a ß-Hydroxy-ß-methylbutyrate
(HMB)-free acid supplement (Townsend et al., 2013). Another study comparing changes in
markers of monocyte recruitment following an acute bout of high-intensity versus high-volume
lower-body resistance exercise in young resistance-trained males reported that plasma
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concentrations of TNF-α were significantly elevated immediately post-exercise and remained
elevated 30 minutes, 1 hour, and 2 hours post-exercise for both trials combined. Interestingly,
despite evidence of greater muscle damage caused by the high-intensity protocol compared to the
high-volume protocol, no significant differences in plasma TNF-α levels were observed between
the two trials (Wells et al., 2016). Ostrowski and colleagues (1999), found that plasma
concentrations of TNF-α were elevated 2.3-fold in well-trained males (age 24-37 years; VO2max
53.3-70.2ml min-1 kg-1) 1 hour after running a marathon. Similarly, Starkie et al. (2001) also
reported a significant increase in plasma levels of TNF-α immediately after and 2 hours after a
competitive marathon. Interestingly, the investigators of that study found that circulating
monocytes were not the source of TNF-α, providing evidence for other sources, perhaps
damaged myocytes, of circulating TNF-α following exercise (Starkie et al., 2001).
In contrast, other studies have found no changes in circulating TNF-α following exercise.
Smith and colleagues (2000), reported no significant elevations in circulating TNF-α at any timepoint following an acute bout of high-intensity eccentric bench press and leg curl in young
untrained males. A similar study found that an acute bout of 24 maximal eccentric bicep curls
did not have an effect on plasma levels of TNF-α in untrained young males despite evidence of
muscle damage (Nosaka & Clarkson, 1996). I. Brenner et al. (1999) compared the impact of
strenuous all-out exercise (“all-out” cycling at 90% VO2max for 5 minutes), circuit training (3
sets of 10 repetitions of biceps curl, knee extension, hamstring curl, bench press and leg press at
70% of 1-RM), and prolonged exercise (2 h of cycling at 60-65% VO2max) on markers of
inflammation in moderately fit young (age 24.9 ± 2.3 years) males. That study observed a
significant increase in plasma TNF-α levels three hours after the prolonged exercise protocol but
no significant changes in TNF-α levels following circuit training or the all-out exercise effort (I.
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Brenner et al., 1999). Another study examining the cytokine response to eccentric exercise in
recreationally active young (ages 20-27 years) and elderly (ages 37-75 years) individuals (gender
not specified) found no effect of exercise on plasma TNF-α levels for either group (Toft et al.,
2002).
Several explanations have been proposed for these conflicting findings in circulating
levels of TNF-α following exercise. Due to rapid renal clearance and/or peripheral uptake, TNFα has a short half-life of 14-18 minutes, therefore any increase in circulating TNF-α may not be
accounted for in studies that did not collect blood within that time-frame following exercise
(Bemelmans, Van Tits, & Buurman, 1996; Davies & Hagen, 1997; Suzuki et al., 2002). For
instance, Sprenger and colleagues (1992) found only borderline plasma concentrations of no
statistical significance in 22 trained, long-distance runners covering a distance of 22 kilometers
in less than 2 hours. Yet, urine concentrations of TNF-α were significantly elevated immediately
after exercise and remained elevated for an hour after exercise (Sprenger et al., 1992). Also,
some assays fail to detect TNF-α when it is bound to soluble receptors, which have been shown
to be released following exercise (Ostrowski et al., 1999; Tilz et al., 1993). Soluble receptors for
TNF-α may inactivate circulating TNF-α and enhance its clearance from circulation, therefore
accounting for the short half-life of TNF-α and failure to detect an increase following exercise
(Bemelmans et al., 1996; Jablonska, Jablonski, & Holownia, 2000; Suzuki et al., 2002). It has
also been suggested that resistance-trained individuals may have a more robust TNF-α response
to exercise than untrained individuals, therefore accounting for the increases found in some
studies but not others (Nosaka & Clarkson, 1996; Smith et al., 2000; Townsend et al., 2013;
Wells et al., 2016). Taken together, evidence suggests that the production, action, and detection
of circulating TNF-α can be blocked by multiple mechanisms.
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TNF-α receptors
The two tumor necrosis factor receptor (TNFR) molecules are TNFR1, a 55kDa receptor
also called TNFR-P55; and TNFR2, a 75kDa receptor also called TNFR-P75 (Fiers, 1991). The
expression of TNF-α receptors can range anywhere from 200-10,000 receptors per cell with 40%
being TNFR1 and 60% being TNFR2 (murine model) (Fiers, 1991). Both of these can bind
membrane-bound TNF-α as well as soluble TNF-α, however, TNFR2 can be fully activated only
by mTNF-α and not by soluble TNF-α (Grell et al., 1995; Sedger & McDermott, 2014; Tartaglia
et al., 1991). Mice lacking either TNFR1 or TNFR2 experience increased levels of TNF-α
relative to controls in response to LPS. This observation indicates that both receptors play a role
in regulating normal TNF-α levels (Peschon et al., 1998). Interestingly, there is evidence to
suggest that the receptors for TNF-α provide the signal for the cellular response rather than the
cytokine itself (Wallach et al., 1991). The wide range of TNF-α functions can be explained by
the presence of these receptors on nearly all cell types. TNFR1 can be found on most human
cells and is considered the receptor through which most of the pro-inflammatory effects are
elicited; whereas TNFR2 is found on vascular endothelial cells and immune cells and has both
pro- and anti-inflammatory roles (Aggarwal, 2003; MacEwan, 2002). Furthermore, some
evidence suggests that TNFR2 may act as a “catcher” by binding TNF-α and delivering it to
TNFR1 during low concentrations of TNF-α, given that TNFR2 has a higher affinity to its ligand
(Bemelmans et al., 1996; Tartaglia et al., 1991).
Though the extracellular domains of each receptor are similar in structure and can both
bind TNF-α, their intracellular domains are different in that TNFR1 contains a death domain that
enables it to recruit the adaptor molecule TNFR1-associated death domain protein (TRADD)
(Aggarwal, 2003; D. Brenner, Blaser, & Mak, 2015; Sedger & McDermott, 2014). TNFR2, on
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the other hand, lacks the death domain and instead recruits TNFR-associated factor 1 (TRAF1)
and TRAF2. A key difference in the binding of each receptor is that the TNFR2-TRAF1/TRAF2
signaling cascade promotes cell survival, while TNFR1-TRADD can result in either cell survival
or cell death depending on the downstream signaling events and cellular context (D. Brenner et
al., 2015). Mice deficient in TRAF2 are born with a systematically smaller muscle mass,
indicating a role of TNFR2-TRAF2 in skeletal muscle development (MacLachlan & Giordano,
1998). Due to the complexity of the signaling events that occur after the binding of each
molecule, predicting the outcome of TNF-α-mediated signaling is challenging.
Skeletal muscles have been shown to express both TNFR1 and TNFR2, and produce
TNF-α (Li & Reid, 2001; Saghizadeh et al., 1996; Tartaglia & Goeddel, 1992). The binding of
TNF-α to either TNFR1 or TNFR2 can activate nuclear factor-κB (NF-κB), however, the
signaling cascades that lead from each receptor to the activation NF-κB are different (D. Brenner
et al., 2015). TNF-α activation of NF-κB has been observed in differentiated myofibers; leading
to reductions in total protein content and loss of adult myosin heavy chain content (Li, Schwartz,
Waddell, Holloway, & Reid, 1998).
Soluble TNF-α Receptors
Similar to the TNF-α cytokine, both TNFR1 and TNFR2 are cleaved from the cell
surface by TACE, turning them into their soluble forms (STNFR1 and STNFR2) in response to
stimulation of the cell (Giai et al., 2013; Gooz, 2010; Wallach et al., 1991). This process
diminishes the amount of receptor available to respond to the ligand and can terminate TNF-α
signaling. STNFR1 and STNFR2 retain the ability to bind to TNF-α and may function to
sequester the TNF-α ligand and act as endogenous inhibitors of TNF-α (Blobel, 2005; Giai et al.,
2013; Van Zee et al., 1992). In neutrophils, surface expression of both receptors decreases
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considerably when exposed to TNF-α due to both ectodomain shedding and internalization
(Porteu & Nathan, 1990; Porteu & Hieblot, 1994; Schleiffenbaum & Fehr, 1990). Porteu &
Hieblot (1994) found that surface expression of both TNFR1 and TNFR2 on human neutrophils
is reduced when exposed to TNF-α in vitro, however, the mechanisms for this TNF-α-induced
decrease in surface expression of each receptor differs in that it led to internalization of TNFR1
and ectodomain shedding of TNFR2. Both STNFR1 and STNFR2 are found in small amounts
(1-3 ng/ml) in the serum of healthy individuals, with dramatic increases found in pathological
states including: autoimmune diseases, infectious disease, and other inflammatory events (Nicod,
1993; Wallach et al., 1991). This indicates a way for cells to protect themselves from the harmful
effects of excess TNF-α levels found in the serum of diseased patients (Wallach et al., 1991).
One example of this is a condition known as TRAPS (TNF-receptor-associated periodic febrile
syndrome). Individuals that suffer from TRAPS have genetic mutations in the cleavage site of
TNFR1 that prevent or reduce ectodomain shedding and downregulation of the receptor (Blobel,
2005; McDermott et al., 1999). Consequently, TNFR1 accumulates on the cell surface and
therefore the cell becomes more susceptible to TNF-α, which causes chronic fevers and
inflammation (Blobel, 2005; McDermott et al., 1999).
Despite STNFR’s ability to prevent overstimulation of the target cell by TNF-α, the
“TNF-α-STNFR” complex remains in circulation, prolonging TNF-α’s ability to bind once it’s
released from the complex (Aderka et al., 1992; van Deuren, 1994). Indeed, Aderka and
colleagues (1992) suggested that both STNFR1 and STNFR2 may augment the effects of TNF-α
by binding and preventing the denaturation of the molecule, thereby serving as a “slow release
reservoir” of available TNF-α. This is of interest because, given that circulating concentrations of
TNF-α decline rather quickly due to its short half-life, observing STNFR levels following muscle
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damage may be of more value for monitoring the inflammatory response. The prolonged
elevation in serum STNFR following an inflammatory event may be due to either ongoing
production or slower clearance (van Deuren, 1994).
TNF-α receptors in exercise
Research studies on the effects of exercise on TNFR expression are limited. The study by
Townsend and colleagues (2013) mentioned earlier reported a significant increase in TNFR1
expression on monocytes 30-minutes post-exercise. This increase in TNFR1 expression may
explain why there was an increase in plasma TNF-α immediately following exercise, but not at
30 minutes post-exercise (Townsend et al., 2013). Wells and colleagues (2016), on the other
hand, reported no change in TNFR1 expression on monocytes following resistance exercise
despite reporting significant increases in serum TNF-α. Human monocytes can be divided into
three subsets: classical, intermediate, and non-classical (Ziegler-Heitbrock et al., 2010). Research
suggests that intermediate monocytes express the highest surface expression of TNFR1
compared to the other monocyte subpopulations while non-classical monocytes express the
highest surface expression of TNFR2 (Hijdra, Vorselaars, Grutters, Claessen, & Rijkers, 2012).
Wells et al. (2016) observed changes in TNFR1 expression on classical monocytes only, while
Townsend et al. (2013) observed changes in TNFR1 expression on all monocyte subsets.
Therefore, it is possible that TNFR1 expression is not changed in classical monocytes as a
response to exercise, but it is in intermediate and/or in non-classical monocytes (Wells et al.,
2016).
Research studies on the effects of exercise on circulating levels of soluble TNF-α
receptors are lacking. A study mentioned earlier in this review by Ostrowski and colleagues
(1999) found that plasma concentrations of STNFR1 and STNFR2 increased 2.7- and 1.6-fold 1
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hour after well-trained males ran a marathon, respectively. These increases in STNFRs paralleled
the increase in circulating TNF-α, demonstrating a regulating mechanism for TNF-α (Ostrowski
et al., 1999). Tilz et al. (1993) measured the plasma concentration of STNFR (specific type not
known) in 18 young males with hiking experience during a hiking tour in the Austrian Alps.
Compared to baseline, a significant increase in STNFR was observed 3 hours into the tour (at the
top of the mountain), at the end of the tour (5 hours after the start), and 24 hours after the start of
the tour. This study did not measure circulating levels of TNF-α, therefore no speculation can be
made about the role of STNFRs in regulating inflammation (Tilz et al., 1993). Despite these
findings, no study up to this point has observed the effects of resistance training and muscle
damage on circulating levels of STNFRs.
TNF-α and Aging
The loss of muscle mass and function due to aging, termed sarcopenia, is linked to an
increase in all-cause mortality (Cooper et al., 2010). Since skeletal muscle is the main
determinant of resting metabolic rate and the primary site for glucose and fat disposal, the agerelated loss of muscle mass may lead to increased adiposity, dyslipidemia, and insulin resistance
(Buford et al., 2010; Greiwe et al., 2001). The age-associated decrements in muscle mass and
function are a consequence of several distinct mechanisms. One such mechanism involves the
immune system and its role in skeletal muscle metabolism. Aging adults are more susceptible to
severe infections, take longer to recover from infections and are frequently less responsive to
vaccination. This is partly due to immunosenescence, the functional deterioration of the immune
system as a result of aging (Panda et al., 2009). The mechanisms underlying the age-associated
detriments in immunity include decreased expression and functioning of receptors and defects in
signaling pathways (Kohut & Senchina, 2004). Though T cell lymphocytes have been studied to
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the greatest extent and appear to be most affected by aging, immunosenescence can affect both
the adaptive and innate immune systems. Because aging leads to a functional deterioration of the
innate immune system, and the innate immune system plays a significant role in recovery from
exercise, immunosenescence may play a role in the age-associated loss of skeletal muscle mass
and function.
TNF-α and muscle loss
While sarcopenia is characterized as the age-associated loss of muscle mass, cachexia is
the cytokine-associated wasting of roughly equal amounts of fat and muscle mass and is
associated with several pathologies such as cancer, HIV/AIDS, and rheumatoid arthritis among
others (Thomas, 2007). However, elevated levels of pro-inflammatory cytokines have also been
found in otherwise healthy older individuals. One study compared the plasma levels of TNF-α
and TNFR2 between adults of four different age ranges and found that 100-year-olds have
significantly higher levels of TNF-α and STNFR2 compared to 80-year-olds, 55-65-year-olds,
and 18-30-year-olds. TNF-α and STNFR2 were also significantly higher in 80-year-olds
compared to 18-30-year-olds (Bruunsgaard et al., 1999). Similar findings were observed by Rall
and colleagues (1996). They found that stimulated production of TNF-α at baseline was 50%
greater among healthy elderly individuals (65-80 years) compared to younger individuals (22-30
years). No differences in unstimulated production of TNF-α were observed between groups at
baseline; however, the same pattern of higher production in older subjects compared with young
subjects was observed (Rall et al., 1996). In muscle, TNF-α protein and mRNA content is
significantly higher in frail elderly subjects compared to young subjects (Greiwe et al., 2001).
Increased levels of TNF-α are associated with lower muscle mass and lower muscle strength in
otherwise healthy older adults. Visser and colleagues (2002) observed a 1.2-1.3 kg decrease in
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grip strength for each standard deviation increase in plasma TNF-α. It appears that the
mechanisms involved in cachexia include both reduced protein synthesis and increase protein
degradation, though protein degradation is the major cause (Thomas, 2007).
Overnight infusion of murine TNF-α in vivo has been shown to reduce circulating levels
of IGF-1, as well as decrease the local content of IGF-I in skeletal muscle in fasted rats (Fan,
Char, Bagby, Gelato, & Lang, 1995). The infusion paradigm used in that study was chosen to
simulate the relatively low levels of TNF-α detected in the circulation of humans during chronic
inflammation or other catabolic illnesses. The TNF-α-induced decrease in IGF-1 may be
responsible for the increase in protein degradation and reduced protein synthesis seen in
conditions involving the overproduction of pro-inflammatory cytokines (Fan et al., 1995). Acute
infusion of TNF-α in rats has also been shown to decrease muscle protein synthesis and increase
protein breakdown (García-Martínez, López-Soriano, & Argilés, 1993). Frost and colleagues
(1997) demonstrated that TNF-α directly inhibits protein synthesis in human myoblasts and
myotubes; both at the basal level and when stimulated by IGF-1. Greiwe and colleagues (2001)
reported an inverse relationship between muscle protein synthesis and muscle TNF-α protein
content in frail elderly adults. The investigators also observed that resistance training
coordinately decreased skeletal muscle TNF-α content and increased protein synthesis rate.
These findings supports the hypothesis that elevated levels of TNF-α may negatively impact
muscle hypertrophy, and that the positive effects of exercise on the elderly population may
involve alterations in the concentration of a potentially detrimental cytokine in muscle (Greiwe
et al., 2001).
Very few research studies have compared the acute response of TNF-α to exercise in
older adults compared to younger adults. In a study by Hamada and colleagues (2005), there was
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a trend toward a blunted accumulation of TNF-α in the muscle of the elderly men compared to
the young men following an acute bout of eccentric exercise during the repair phase of muscle
damage. Likewise, an age-associated decrease in leukocyte recruitment was reported in this
study. Interestingly, the older group saw a significantly greater increase in IL-1ß gene expression
compared to the younger group, suggesting a compensatory role of IL-1ß produced in muscle for
the age-associated reduction of TNF-α (Hamada et al., 2005).
Conclusions
Despite our current knowledge of TNF-α’s role in skeletal muscle regeneration following
muscle damage, whether or not aging affects this response is unclear. Furthermore, although
higher plasma concentrations of TNF-α are associated with lower muscle mass and lower muscle
strength in healthy older men and may contribute to sarcopenia, whether this relationship is
apparent earlier in life (middle-age) is unknown. Also, the relationship between STNFR1 and
STNFR2 and muscle mass and strength has not been determined. Therefore, the purpose of the
current study was to compare changes in plasma levels of TNF-α and STNFRs in response to
muscle damage in young and middle-aged males. The relationship between circulating levels of
TNF-α, STNFR1, and STNFR2 and isokinetic strength following muscle damage was also
examined. A secondary purpose was to examine the relationship between baseline levels of
TNF-α, STNFR1 and STNFR2 and muscle size and strength in middle-aged males to determine
if TNF-α levels may indicate early signs of muscle wasting related to aging. We hypothesized
that middle-aged males would show higher baseline levels of TNF-α, STNFR1, and STNFR2
compared to young males. We expected to see a negative relationship between TNF-α/STNFRs
and muscle size/strength. We also anticipated a significant increase in circulating levels of TNFα, STNFR1, and STNFR2 in both groups, though this response would be blunted in the middle26

aged group compared to the young group. Lastly, the middle-aged group would take longer to
recover their strength following muscle damage compared to the young group.
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CHAPTER THREE: METHODOLOGY

Participants
Using the procedures described by Beck (2013), a minimum sample size of nine
participants per group produced a statistical power (1-β) of 0.80 at an alpha level of 0.05. Power
calculations were made using G*Power statistical analyses software (Version 3.1.9.2,
Düsseldorf, Germany) and were based upon an effect size (dz) of 1.51 generated from changes in
plasma TNF-α from baseline to 30-minutes post resistance exercise reported by Wells et al.
(2016) for the volume group. Twenty-five recreationally active males were recruited to
participate in this experimental study. Study participants were recruited into two groups based on
age. The young-age group (YA; N=12) consisted of males between the ages of 18 – 30 while the
middle-aged group (MA; N=13) consisted of males between the ages of 40 – 60 years. Inclusion
criteria required participants to be recreationally active during the past 6 months as defined by
the American College of Sports Medicine (150 minutes of exercise/week) including resistance
exercise (Garber et al., 2011). All participants were free of any physical limitations that may
have affected performance. Additionally, all participants were free of any medications,
performance enhancing drugs, and any dietary supplements that have antioxidant or recovery
properties (creatine, beta-alanine etc.) as determined by a health and activity questionnaire.
Following an explanation of all procedures, risks and benefits, each participant provided his
informed consent prior to participation in this study. The research protocol and the informed
consent document were approved by the New England Institutional Review Board prior to
participant enrollment (NEIRB# 120160966, Approved 20 January 2017).
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Study Design
Both groups reported to the human performance laboratory (HPL) on four separate
occasions (Figure 3). On the first visit (T1), participants were assessed for anthropometrics
including height, weight, and body fat percentage. Following anthropometric assessment,
participants performed a standardized warm-up. After the warm-up, the participants completed a
familiarization protocol on the isokinetic device with the purpose of familiarizing the participants
with the motions involved in the lower body performance assessment. On the second visit (T2),
participants arrived at the HPL following a 10-hour fast and completed baseline (BL) testing,
which included an ultrasound assessment, a blood draw, and a lower body performance
assessment. After a brief rest period, participants then completed a muscle damaging protocol
(MDP). Immediately after the MDP (IP), participants again completed the lower body
performance assessment to determine decrements in performance as a result of the MDP.
Follow-up lower body performance assessments were also conducted 120-minutes (120P), 24hours (24H), and 48-hours (48H) post-MDP. Follow-up blood samples were collected from each
participant at IP, 30-minutes (30P), 60-minutes (60P), 120P, 24H, and 48H post-MDP.
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Figure 3: Study Design
Participants were assessed for anthropometrics and completed a familiarization protocol
at least 48 hours prior to the muscle damaging protocol (T1). On visit 2 (T2), participants
completed a muscle damaging protocol, provided blood samples at baseline (BL),
immediately post- (IP), 30 minutes post- (30P), 60 minutes post- (60P), 120 minutes post(120P), 24 hours (24H) post-, and 48 hours (48H) post-muscle damaging protocol. An
ultrasound assessment was completed at BL. Lower body performance testing was
completed at BL, IP, 120P, 24H, and 48H.

Procedures
Dietary Recall
Participants were asked to provide a 3-day dietary recall beginning on the day prior to T2
through T3 while maintaining the same caloric intake, macronutrient proportions and nutrient
timing for the duration of the investigation. FoodWorks nutrient analysis software (McGrawHill, New York, N.Y., USA) was used to analyze the self-reported dietary recalls for total
kilocalorie intake and macronutrient proportions (carbohydrate, protein, and fat). Additionally,
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participants were asked to abstain from any nonsteroidal anti-inflammatory drugs, cryotherapy,
or any other agents that may affect inflammation.
Anthropometric Measurements
At T1, body mass (±0.1 kg) and height (±0.1 cm) were measured using a Health-o-meter
Professional scale (Patient Weighing Scale, Model 500 KL, Pelstar, Alsip, IL, USA). Body
composition was assessed using a direct segmental multi-frequency bioelectrical impedance
analyzer (BIA) via InBody (Model 770, InBody Co., Ltd, Cerritos, CA, USA) according to the
manufacture’s guidelines. BIA estimates body composition using the conductivity differences of
the various tissues due to their tissue characteristics (water and electrolyte content). This
analyzer processes 30 impedance measurements by using six different frequencies (1, 5, 50, 250,
500, 1000 kHz) at each of five segments of the body (right arm, left arm, trunk, right leg, left leg)
using tetrapolar 8-point tactile electrodes (Kurinami et al., 2016). Participants were asked to
remove all jewelry and footwear, including socks; and to void the bladder before performing the
test. This assessment required the participants to wipe their hands and feet with an InBody tissue
to enhance electrical conductivity and reduce surface bacteria before being assessed. The
participants were then instructed to stand on the InBody platform electrodes while holding two
hand electrodes out to the side. They held this position for one minute as the device conducted
the electrical currents through the body to determine body composition. Values for total body fat
percentage were recorded.
Familiarization
Following anthropometric testing, participants performed a familiarization protocol to
become acquainted with the Biodex S4 isokinetic dynamometer (Biodex Medical System, Inc.,
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New York, NY, USA). Prior to the familiarization protocol, participants performed a
standardized warm-up consisting of five minutes on a cycle ergometer against a light resistance.
Following the warm-up, participants were seated in the isokinetic dynamometer, positioned with
a hip angle of 110° and strapped into the chair at the waist, shoulders, and across the thigh
(Beyer et al., 2016). The chair and dynamometer settings were adjusted for each participant to
properly align the axis of rotation with the lateral condyle of the femur. All participants were
tested on their right leg which was secured to the dynamometer arm just above the medial and
lateral malleoli. Isokinetic dynamometer settings for each individual were recorded and remained
consistent throughout the study. The familiarization protocol included two maximal voluntary
isometric contractions (MVIC) at a knee angle of 110° of extension (180° representing full
extension); three sets of three repetitions of isokinetic concentric contractions at angular
velocities of 60°/sec, 240°/sec, and 180°/sec, respectively; and 1 set of 10 repetitions of
isokinetic concentric/eccentric contractions at angular velocities of 60°/sec for both the
concentric and eccentric phase.
Ultrasound Assessment
Participants were assessed at BL for muscle size and quality using noninvasive
ultrasonography of the rectus femoris (RF) muscle. Participants were asked to lie supine on an
examination table for a minimum of fifteen minutes to allow for consistent muscle measurements
(Berg, Tedner, & Tesch, 1993). The participants remained in a supine position, with their legs
extended and a towel placed underneath the popliteal fossa of the right leg, allowing for a slight
bend at the knee (Mangine et al., 2015). Ultrasound measurements were made using a 12-MHz
linear probe (General Electric LOGIQe, Wauwatosa, WI, USA) coated with a water-soluble
ultrasound gel (Aquasonic Clear, Parker Laboratories Inc., Fairfield, NJ, USA). Images were
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captured at 50% of the straight line distance between the anterior inferior iliac crest and proximal
border of the patella with gain set at 50 dB, dynamic range set at 72, and depth fixed at 6 cm
(Boone, Stout, Beyer, Fukuda, & Hoffman, 2015; Mangine et al., 2015). Cross-sectional area
(CSA) of the RF was measured using transverse panoramic images, while muscle thickness (MT)
was measured using longitudinal still images. To ensure consistency, the same technician
positioned each participant, collected all images, and analyzed each image.
ImageJ software (National Institute of Health, USA, version 1.48) was utilized to analyze
the ultrasound images using a known distance of 1 cm on the ultrasound image to calibrate the
software (Wells et al., 2014). To measure CSA, the polygon tool of the ImageJ software was
used to trace the outline of the muscle from the transverse panoramic image while avoiding the
surrounding bone and fascia. The ImageJ software calculated the area (± 0.1 cm2) contained
within the traced muscle image. Echo intensity (EI) was measured from the transverse panoramic
images using the standard histogram function, which measures the greyscale of each pixel in
arbitrary units (AU). EI may provide a measure of muscle ‘quality’ by delineating the ratio of
contractile to non-contractile tissues within the ultrasound image (Fukumoto et al., 2012). MT
was determined as the straight-line distance (±0.1 cm) between the superior border of the deep
aponeurosis and the inferior border of the superficial aponeurosis. Three images of each
measurement were taken, and the mean of the three measurements was recorded. Intra-class
correlation coefficients for the ultrasound technician were determined from a repeated-measures
analysis of 10 individuals separated by 24 hours [CSA= 0.96, SE = 0.78 cm2; MT = 0.94, SE =
0.21 cm; EI= 0.94, SE= 3.88 AU].
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Blood Measurements
Blood samples were collected at seven time points throughout the study (BL, IP, 30P,
60P, 120P, 24H, and 48H). The blood samples on T2 (BL, IP, 30P, 60P and 120P) were obtained
using a Teflon cannula placed in a superficial forearm vein and plastic syringe. The cannula was
maintained patent using a non-heparinized isotonic saline solution (Becton Dickinson, Franklin
Lakes, NJ, USA). The blood samples from 24H and 48H were collected using a 21 gauge, 1 ¼
inch Vacutainer blood collection needle. Participants were instructed to lie supine for 15
minutes prior to each blood draw.
A total of 20 mL of blood was collected at each time-point in two, 10 mL Vacutainer®
tubes: one containing K2EDTA, which is an anticoagulant to prevent the blood from clotting, and
a serum tube where the blood was allowed to clot. An aliquot of whole blood from the K2EDTA
tube was immediately utilized to assess hematocrit, hemoglobin, and red blood cell count. The
remaining blood in the EDTA tube was subsequently centrifuged at 4, 000g for 15 minutes.
Blood in the serum tube was allowed to clot at room temperature before being centrifuged. The
resulting plasma and serum samples were placed into separate 1.8-mL microcentrifuge tubes and
frozen at -80° C for later analysis.
Lower-Body Performance
The lower body performance assessment was performed on five occasions throughout the
study (BL, IP, 120P, 24H, and 48H) and was composed of 1 set of 3 repetitions of isokinetic
contractions. The isokinetic contractions were concentric knee extensions at an angular velocity
of 180°/sec. Values of peak torque (PTQ), mean torque (mTQ), peak power (PP), and mean
power (mP) were recorded for each contraction at each time point. The lever arm of the
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dynamometer was programmed to extend the participant’s leg from 95° of knee flexion to 155°
of knee flexion (where 180° is full extension).
Muscle Damaging Protocol
After completing the initial lower-body performance assessment, participants were seated
in the isokinetic dynamometer chair. Following a five-minute rest, participants performed the
MDP. The MDP was composed of 8 sets of 10 repetitions, consisting of concentric knee
extension (60°/sec) and eccentric knee flexion (60°/sec). The range of motion for each repetition
of the MDP was from 95° of knee flexion to 155° of knee flexion. Participants were instructed to
give maximal effort during this protocol. Participants were provided with one minute of rest
between each set of the MDP. The lower body performance assessment at IP was performed five
minutes after the conclusion of the MDP.
Biochemical Analysis
Blood lactate concentrations were analyzed from plasma using an automated analyzer
(Analox GM7 enzymatic metabolite analyzer, Analox instruments USA, Lunenburg, MA, USA).
Hematocrit and hemoglobin were analyzed in whole blood using a complete blood cell counter
(Coulter ® AC ●T diff 2™ hematology analyzer). Plasma volume shifts were calculated using
the formula established by Dill & Costill (1974). To eliminate inter-assay variance, all samples
were analyzed in duplicate by a single technician. Coefficient of variation for each assay was
2.04% for blood lactate; 1.63% for hematocrit; and 1.10% for hemoglobin.
Serum concentrations of myoglobin (Calbiotech, Spring Valley, CA, USA), STNFR1,
and STNFR2 (RayBiotech, Inc, GA, USA) were obtained via commercially available enzymelinked immunosorbent assay (ELISA); while creatine kinase (CK) was analyzed using a
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commercially available kinetic assay (Sekisui Diagnostics, Charlottetown, PE, Canada), per
manufacturer’s instructions. To limit inter-assay variability, all samples for a particular assay
were thawed once, and analyzed in duplicate by the same technician using a BioTek Eon
spectrophotometer (BioTek, Winooski, VT, USA). Coefficients of variation for each assay were
5.03% for myoglobin; 4.50% for CK; 2.91% for STNFR1; and 2.34% for STNFR2.
Plasma concentrations of TNF-α were analyzed via high-sensitivity cytokine multiplex
assay (Luminex., Cat no. FCSTM09-02; R&D systems, Inc. Minneapolis, MN, USA) on a
MAGPIX instrument (Luminex, Austin, TX), according to the manufacturer's instructions. All
samples were run in duplicate with a mean intra-assay coefficient of variance of 3.32%.
Statistical Analysis
Prior to statistical procedures, all data was assessed for sphericity. If the assumption of
sphericity was violated, a Greenhouse-Geisser correction was applied. Biochemical and
performance changes were analyzed using a two factor (time x group) repeated measures
analysis of variance (ANOVA). In the event of a significant F ratio, least significant difference
(LSD) post-hoc analysis were used for pairwise comparisons. If a significant interaction was
observed, follow-up one way repeated measures ANOVA were used to determine time effects
for each treatment and independent t-tests were used for pairwise comparisons between groups at
each time point. Comparisons between treatments were further analyzed using Cohen’s d.
Magnitudes of the standardized effects were interpreted using thresholds of <0.2, 0.2-0.6, 0.61.2, 1.2-2.0, 2.0-4.0. These values correspond to trivial, small, moderate, large and very large
effect size (ES), respectively. Time effects were further analyzed using partial eta squared (η2p).
Interpretations of η2p were evaluated in accordance with Cohen (1988) at the following levels:
small effect (0.01-0.058), medium effect (0.059-0.137) and large effect (> 0.138). The net area
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under the curve (AUC) was also calculated for biochemical measures from BL-120P using a
standard trapezoidal technique, and was assessed using independent t-tests. Additionally,
Pearson product moment correlations were calculated to examine selected bivariate relationships
between biochemical markers, performance variables, age, and muscle morphological
characteristics. Significance was accepted at an alpha level of p ≤ 0.05. Data were analyzed using
IBM SPSS Statistics for Windows (version 21.0; IBM Corp., Armonk, N.Y., USA). All data are
reported as mean ± SD, unless otherwise stated.
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CHAPTER FOUR: RESULTS

Participant Characteristics
Following an explanation of all procedures, risks and benefits, a total of 25 participants
were enrolled in this study (YA = 12; MA = 13). Five participants were removed from the
investigation prior to analysis (YA= 2; MA= 3). Of the five participants that were removed, two
participants discontinued testing following the familiarization protocol due to knee discomfort
(YA= 1, MA= 1), two reported recent or current consumption of recovery-enhancing
supplements after being enrolled but prior to testing (YA= 1, MA=1), and one reported a
metabolic disease after being enrolled but prior to testing (MA group). One participant
completed testing but was excluded from the analysis due to indications of muscle damage
unrelated to the intervention at baseline (YA group). Therefore, 9 participants were included in
the analysis for YA (21.8 ± 2.2 y, 179.5 ± 4.9 cm, 91.2 ± 12.2 kg, 21.8 ± 4.3% BF) and 10 for
MA (47.0 ± 4.4 y, 176.8 ± 7.6 cm; 96.0 ± 21.5 kg, 25.4 ± 5.3% BF) for a total of 19 participants.
A graphical schematic of this is shown in Figure 4. Characteristics of the participants included in
the analysis are listed in Table 1. Aside from age, no significant differences were observed
between groups for participant characteristics.
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Figure 4: Participant recruitment
Participant recruitment and enrollment.
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Table 1: Participant Characteristics

Young Age (YA)

Middle-Aged (MA)

p

n

9

10

N/A

Age (Yrs)

21.8
(2.2)

47.0
(4.4)

< 0.001*

Height (cm)

179.5
(4.9)

176.8
(7.6)

0.39

Weight (kg)

91.2
(12.2)

96.0
(21.5)

0.559

Body Fat (%)

21.8
(4.3)

25.4
(5.3)

0.126

MT (cm)

2.62
(0.39)

2.37
(0.40)

0.182

CSA (cm2)

13.83
(2.32)

14.26
(1.61)

0.642

Characteristics

84.68
95.23
0.061
(11.60)
(11.30)
Participant characteristics are shown as mean (SD). Muscle thickness (MT), crosssectional area (CSA), and echo intensity (EI) of the rectus femoris were measured at
baseline.
*Significant group difference (p < 0.05).
EI (AU)

40

Dietary Intake
Dietary intake is presented in Table 2. No time x group interaction, main effect for group,
or main effect for time was noted for caloric intake or macronutrient intake over the course of the
three days (p’s > 0.05). No significant differences were observed in mean or total caloric intake
or any macronutrient intake (p’s > 0.05).
Table 2: Dietary Intake
Day 1

Day 2

Day 3

Mean

Total

2361.4
(820.0)
1912.4
(862.0)

1836.0
(757.0)
2019.5
(628.7)

2031.1
(757.0)
1994.0
(516.7)

2076.2
(542.2)
1975.3
(520.4)

6228.5
(1635.5)
5925.9
(1561.2)

141.9
(70.8)
90.8
(39.5)

90.6
(50.1)
100.0
(29.9)

98.0
(62.8)
93.5
(23.7)

110.2
(43.8)
94.8
(21.6)

330.5
(131.5)
284.3
(64.7)

220.4
(93.4)
224.5
(120.6)

206.3
(85.7)
207.6
(71.2)

234.3
(101.2)
242.4
(100.1)

220.3
(70.2)
224.8
(69.1)

661.0
(210.6)
674.5
(207.2)

Caloric Intake (kcal)
YA (n=9)
MA (n=10)
Protein Intake (g)
YA (n=9)
MA (n=10)
Carbohydrate Intake (g)
YA (n=9)
MA (n=10)
Fat Intake (g)
88.5
73.0
66.6
76.0
228.1
(56.1)
(37.5)
(25.9)
(27.4)
(82.2)
70.9
85.9
79.0
78.6
235.8
MA (n=10)
(48.4)
(44.2)
(32.8)
(32.9)
(98.6)
Groups: YA = Young Age; MA = Middle-Aged. Participants provided a 3-day dietary
recall beginning on the day prior to T2 (Day 1) through T3 (Day 3). Daily, mean, and
total caloric intake, protein intake, carbohydrate intake, and fat intake were analyzed and
are shown as mean (SD).
YA (n=9)
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Changes in Lower Body Performance
Total Work Done
Total work done during MDP is shown in Figure 5. No significant difference was
observed between groups on total work done during MDP (p = 0.994).

Figure 5: Total Work Done during MDP
Total work done during the muscle damaging protocol (MDP) was analyzed and is
reported in joules (J) as means ± SD.
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Peak Torque and Mean Torque
Changes in PTQ and mTQ in response to MDP are depicted in Figure 6. No significant
group x time interaction (p = 0.068) or main group effect (p = 0.071) was observed for PTQ.
When collapsed across groups, a significant time effect was observed (F = 14.3; p < 0.001; η2p =
0.457). With both groups combined, significant decreases in PTQ were observed at IP (p <
0.001), 120P (p = 0.016), 24H (p = 0.012) and 48H (p = 0.006) relative to BL.
A significant group x time interaction was observed for mTQ (F = 3.2; p = 0.019; η2p =
0.156). Significant decreases in mTQ were observed at IP (p = 0.001), 120P (p = 0.031), and
48H (p = 0.046) relative to BL for the YA group. Significant decreases were observed at IP (p <
0.001) and 24H (p = 0.035) relative to BL for the MA group. A significantly higher mTQ was
observed in the YA group at BL compared to the MA group (p = 0.050). No other between group
differences were noted.
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Figure 6: Changes in Peak Torque and Mean Torque
Young age (YA) and Middle-Aged (MA) groups were analyzed for changes in peak
torque (PTQ) and mean torque (mTQ). Values are shown as newton meters (NM) at
baseline (BL), immediately post- (IP), 120 minutes post-(120P), 24 hours (24H) post-,
and 48 hours (48H) post-muscle damaging protocol. Data shown as means ± SD.
# Significantly different from BL when collapsed across groups (p < 0.05)
† Significant difference between YA and MA
* Significantly different from BL for YA (p < 0.05)
^ Significantly different from BL for MA (p < 0.05)
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Peak Power and Mean Power
Changes in PP and mP in response to MDP are depicted in Figure 7. No significant group
x time interaction (p = 0.156) or main effect for group (p = 0.116) was observed for PP. When
collapsed across groups, a significant time effect was observed for PP (F = 10.4; p < 0.001; η2p =
0.379). With both groups combined, a significant decrease in PP was observed at IP (p < 0.001)
relative to BL.
No significant group x time interaction (p = 0.093) or main effect for group (p = 0.208)
was observed for mP. When collapsed across groups, a significant time effect was observed for
mP (F = 13.1; p < 0.001; η2p = 0.434). With both groups combined, significant decreases in mP
were observed at IP (p < 0.001) and 120P (p = 0.025) relative to BL.
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Figure 7: Changes in Peak Power and Mean Power
Young age (YA) and Middle-Aged (MA) groups were analyzed for changes in peak
power (PP) and mean power (mP). Values are shown as watts (W) at baseline (BL),
immediately post- (IP), 120 minutes post-(120P), 24 hours (24H) post-, and 48 hours
(48H) post-muscle damaging protocol. Data shown as means ± SD.
# Significantly different from BL when collapsed across groups (p < 0.05)
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Biochemical Analysis
Lactate
Changes in plasma lactate concentrations are shown in Table 3. No significant time x
group interaction (p = 0.215) or main effect for group was noted (p = 0.096); however, when
collapsed across groups, a significant time effect was observed (F = 51.1; p < 0.001; η2p =
0.773). With both groups combined, significant elevations in plasma lactate concentrations were
observed at IP (p < 0.001) and 30P (p = 0.003) relative to BL. AUC analysis revealed no
significant difference between groups (p = 0.362)
Table 3: Changes in lactate concentrations
Lactate (mmol/L)
Group
BL
IP
30P
60P
YA
1.76 ± 0.53
4.91 ± 1.80‡
2.59 ± 0.82‡
1.79 ± 0.32
MA
1.54 ± 0.44
3.77 ± 1.10‡
2.13 ± 0.43‡
1.63 ± 0.33
Plasma lactate concentrations before (BL), immediately post- (IP), 30 minutes post(30P), and 60 minutes post- (60P) muscle damaging protocol in the young age (YA) and
middle-aged (MA) groups. ‡ = Significant increase relative to BL when groups are
combined (p < 0.05). Data shown as means ± SD.
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Myoglobin
Changes in circulating myoglobin concentrations are presented in Figure 8. No
significant time x group interaction (p = 0.640) or main effect for group was noted (p = 0.641);
however, a significant time effect was observed for circulating myoglobin concentrations (F =
8.7; p = 0.005; η2p = 0.339). With both groups combined, plasma myoglobin was significantly
higher at 30P (p = 0.002), 60P (p = 0.001), and 120P (p = 0.007) relative to BL. AUC analysis
revealed no significant differences between groups (p = 0.710)

Figure 8: Changes in Myoglobin Concentrations
Plasma myoglobin concentrations before (BL), 30 minutes post- (30P), 60 minutes post(60P), and 120 minutes post- (120P) muscle damaging protocol in the young age (YA)
and middle-aged (MA) groups. Data shown as means ± SD.
# Significantly different from BL when collapsed across groups (p < 0.05)
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Creatine Kinase
Changes in circulating CK concentrations are presented in Figure 9. No significant time x
group interaction (p = 0.621) or main effect for group was noted (p = 0.654). A significant time
effect was observed for circulating CK concentrations (F = 8.2; p = 0.001; η2p = 0.328). With
both groups combined, circulating CK was significantly higher at 24H (p = 0.001) and 48H (p =
0.005) relative to BL.

Figure 9: Changes in Creatine Kinase Concentrations
Serum creatine kinase concentrations before (BL), 24 hours (24H) post-, and 48 hours
(48H) post- muscle damaging protocol in the young age (YA) and middle-aged (MA)
groups. Data shown as means ± SD.
# Significantly different from BL when collapsed across groups (p < 0.05)
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Circulating TNF-α, STNFR1, and STNFR2
TNF-α
Changes in plasma TNF-α in response to MDP are depicted in Figure 10. No time x
group interaction, main effect for group, or main effect for time was noted (p’s > 0.05). TNF-α
AUC is presented in Figure 11. AUC analysis revealed no significant differences between groups
(p = 0.289).

Figure 10: Changes in plasma TNF-α
Plasma TNF-α concentrations before (BL), immediately post- (IP), 30 minutes post(30P), 60 minutes post- (60P), 120 minutes post- (120P), 24 hours (24H) post-, and 48
hours (48H) post-muscle damaging protocol in the young age (YA) and middle-aged
(MA) groups. Data shown as means ± SD.
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Figure 11: Tumor Necrosis Factor-alpha (TNF-α) area under the curve (AUC)
Groups: YA = Young Age; MA = Middle-Aged. Data reported as means ± SD.
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STNFR1
Changes in serum STNFR1 in response to MDP are shown in Figure 12. No significant
group x time interaction (p = 0.175) or main effect for group (p = 0.052) was observed for serum
STNFR1. When collapsed across groups, a significant time effect was observed (F = 6.2; p =
0.001; η2p = 0.294). With both groups combined, STNFR1 significantly decreased from BL at
30P (p = 0.001), and was significantly increased relative to BL at 48H (p = 0.028). STNFR1
AUC is presented in Figure 13. AUC analysis revealed no significant differences between groups
(p = 0.170).

Figure 12: Changes in serum STNFR1
Serum STNFR1 concentrations before (BL), immediately post- (IP), 30 minutes post(30P), 60 minutes post- (60P), 120 minutes post- (120P), 24 hours (24H) post-, and 48
hours (48H) post-muscle damaging protocol in the young age (YA) and middle-aged
(MA) groups. Data shown as means ± SD.
# Significantly different from BL when collapsed across groups (p < 0.05)
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Figure 13: Soluble Tumor Necrosis Factor-alpha Receptor 1 (STNFR1) area under the
curve (AUC)
Groups: YA = Young Age; MA = Middle-Aged. Data reported as means ± SD.
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STNFR2
Changes in serum STNFR2 in response to MDP are shown in Figure 14. No significant
group x time interaction (p = 0.213) or main effect for group (p = 0.057) was observed for serum
STNFR2. When collapsed across groups, a significant time effect was observed (F = 6.2; p =
0.013; η2p = 0.292). With both groups combined, STNFR2 significantly decreased from BL at
30P (p = 0.008), 60P (p = 0.003), and 120P (p = 0.002). STNFR2 AUC is presented in Figure
15. AUC analysis revealed no significant differences between groups (p = 0.139).

Figure 14: Changes in serum STNFR2
Serum STNFR2 concentrations before (BL), immediately post- (IP), 30 minutes post(30P), 60 minutes post- (60P), 120 minutes post- (120P), 24 hours (24H) post-, and 48
hours (48H) post-muscle damaging protocol in the young age (YA) and middle-aged
(MA) groups. Data shown as means ± SD.
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Figure 15: Soluble Tumor Necrosis Factor-alpha Receptor 2 (STNFR2) area under the
curve (AUC)
Groups: YA = Young Age; MA = Middle-Aged. Data reported as means ± SD.
Plasma Volume Shifts
No significant group x time interaction (p = 0.470) or main effect for group (p = 0.778)
was observed for plasma volume fluid shifts. When collapsed across groups, a significant time
effect was observed (F = 47.7; p < 0.001; η2p = 0.773). With both groups combined, plasma
volume decreased at IP (-7.6 ± 2.7%), decreased at 30P (-0.3 ± 3.8%), increased at 60P (1.2 ±
3.5%), and decreased at 120P (-1.1± 2.8%). Circulating markers were not corrected for changes
in plasma volume.
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Correlations
A negative correlation was observed between age and STNFR1 at BL (r= -0.462, p =
0.046). Age was also negatively correlated with PTQ (r= -0.527, p = 0.020) and mTQ (r= 0.508, p = 0.026). Age was positively correlated with echo intensity of the rectus femoris at BL
(r= 0.468, p = 0.043). Concentrations of TNF-α were positively correlated with concentrations
of STNFR1 (r= 0. 481, p = 0.037) and STNFR2 (r= 0.692, p = 0.001) at BL. A positive
correlation was observed between concentrations of STNFR1 and STNFR2 at BL (r= 0.480, p =
0.037), IP (r= 0.490, p = 0.046), 60P (r= 0.466, p = 0.044), 120P (r= 0.485, p = 0.035), 24H (r=
0.658, p = 0.002), and 48H (r= 0.599, p = 0.007). No correlations were observed between any of
the lower body performance variables and circulating levels of TNF-α, STNFR1, or STNFR2
(p’s > 0.05).
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CHAPTER FIVE: DISCUSSION
The results of this study indicate that plasma TNF-α and serum STNFRs responses to
muscle damage are similar between young males and middle-aged males. Significant elevations
in myoglobin were observed at 30P, 60P, and 120P relative to BL, while CK was significantly
elevated at 24H and 48H. These changes were not significantly different between groups,
indicating that muscle damage was similar irrespective of age. Muscle damage did not appear to
have an effect on plasma levels of TNF-α. When collapsed across groups, serum STNFR1
concentrations were decreased 30 minutes post-MDP, and were increased 48 hours post-MDP
relative to baseline. Serum STNFR2 concentrations were decreased relative to BL at 30, 60, and
120 minutes post-MDP. Our results indicate that ectodomain shedding of TNFR1 and TNFR2
appears to be attenuated following isokinetic eccentric exercise. This finding indicates that
measuring circulating STNFRs following muscle damage may be a more appropriate method of
assessing the acute inflammatory response compared to measuring plasma TNF-α. Levels of
STNFR1, but not STNFR2, were elevated relative to BL at 48H. Since TNFR1 is the receptor
through which most of TNF-α’s pro-inflammatory signals occur, this finding may indicate a
protective mechanism for cells to defend against excessive inflammatory signaling at 48-hours
post-exercise.
Consistent with others (Nosaka & Clarkson, 1996; Smith et al., 2000), we observed no
significant elevations in plasma levels of TNF-α following exercise. This lack of response may
be due to the rapid peripheral uptake and/or renal clearance that is typical of TNF-α (Bemelmans
et al., 1996; Davies & Hagen, 1997; Suzuki et al., 2002). An IP blood draw was included in the
current study in order to account for TNF-α’s short half-life. It is possible that an increase in rate
of TNF-α synthesis may have been matched by the clearance and/or cell uptake rate and thus no
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increases in TNF-α concentrations were detected. It is also conceivable that the stimulus
provided in this study was not sufficiently robust to evoke an increase in plasma TNF-α.
Previous research from our laboratory has shown significant increases in TNF-α using lowerbody resistance training protocols comprised of multiple sets and multiple exercises at intensities
of 70-90% 1-RM (Townsend et al., 2015; Wells et al., 2016). These protocols utilized larger
amounts of muscle and elicited greater systemic increases in creatine kinase, myoglobin, and
lactate relative to the those observed in the current study, which utilized an isokinetic protocol
involving the knee extensors only. Consequently, it is likely that the volume and amount of
muscle mass involved in exercise is a factor that directly dictates the ensuing inflammatory
response (Nosaka & Clarkson, 1996; Townsend et al., 2013). Taken together, changes in
circulating TNF-α may be difficult to detect, which explains why recent studies observing the
effects of resistance training on inflammatory markers would choose to measure circulating
STNFR1 and/or other pro-inflammatory signals, such as IL-6, in lieu of circulating TNF-α (Forti
et al., 2017).
Serum concentrations of STNFR1 were decreased at 30P relative to baseline. This
finding is in contrast to previous research noting significant elevations in STNFR1 following
exercise (Ostrowski et al., 1999; Tilz et al., 1993). Ostrowoski et al. (1999) and Tilz et al. (1993)
observed significant changes in circulating STNFRs following both a marathon and a hiking
tour, respectively. Thus, it appears that the STNFR1 response to resistance exercise may differ
from that of prolonged endurance exercise. The exact role of STNFR1 is not clear. While some
suggest that ectodomain shedding of TNFRs may act as a method to prevent TNF-α from binding
to the cells, others suggest that STNFRs help prolong the effects of TNF-α by protecting it from
denaturation and maintaining it in circulation (Aderka et al., 1992; Wallach et al., 1991). The
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findings from the present study suggest that an acute bout of exercise may attenuate shedding of
TNFR1 from the cell surface. Pathological conditions characterized by an inhibition of TNFR1
ectodomain shedding have been shown to result in TNF-α-mediated chronic inflammation
(McDermott et al., 1999). Accordingly, the acute decrease in STNFR1 following muscle damage
observed in the present study may be a temporal change that allows for greater TNF-α signaling
(Blobel, 2005; McDermott et al., 1999). Previous research from our laboratory has reported
increased TNFR1 surface expression on monocytes following resistance training (Townsend et
al., 2013). This increase in TNFR1 surface expression may result from a decreased ectodomain
shedding of TNFR1. These results, in combination with the results found in the current study,
indicate a possible role of ectodomain shedding of TNFR1 at regulating the inflammatory
response to muscle damage. Furthermore, STNFR1 was significantly elevated relative to BL at
48H. This finding suggests that increased ectodomain shedding of TNFR1 may occur as a means
of terminating TNF-α signaling in order to protect the host from excessive inflammation
(Wallach et al., 1991).
Serum concentrations of STNFR2 were decreased at 30P, 60P, and 120P relative to
baseline. However, the role of TNFR2 following EIMD is not clear. While TNFR1 is considered
to be the primary pro-inflammatory receptor for TNF-α, TNFR2 is said to have both pro- and
anti-inflammatory roles (Aggarwal, 2003; MacEwan, 2002). Similar to TNFR1, TNFR2 can be
found on immune cells and it has been suggested that TNFR2 serves to facilitate the association
between TNF-α and TNFR1 (Tartaglia et al., 1991). Therefore, attenuating ectodomain shedding
of TNFR2 following exercise may serve to preserve TNFR2 on the cell surface and facilitate
TNF-α signaling through TNFR1. Consistent with this, significant positive correlations between
serum STNFR1 and serum STNFR2 were observed in all but one time-point. Unlike STNFR1,
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STNFR2 was not significantly elevated relative to BL at any time-point. Since TNFR2 does not
contain a death domain and therefore does not directly lead to cell death, it is plausible that
increased ectodomain shedding of this receptor is not necessary (D. Brenner et al., 2015). Future
research examining the effects of resistance training on the acute inflammatory response should
aim to incorporate surface expressions of TNFR2 on immune cells in conjunction with serum
STNFR2 to better understand the role of this receptor.
No significant differences were observed between groups for TNF-α, STNFR1, or
STNFR2 at BL. A study by Brüünsgaard et al. (1999) showed that significant elevations in TNFα and STNFR2 are only apparent in individuals who were 80-years-old or older, with no
differences between 18-30-year-olds and 55-65 year olds. Our findings are consistent with this
notion, since BL TNF-α concentrations were not different between groups. Interestingly
however, a trend towards higher concentrations of both STNFR1 and STNFR2 were observed in
the YA group compared to the MA group. Though not significant, this finding may suggest that
the ability of cells to shed TNFR1 and TNFR2 may decline with age. This speculation is further
reinforced by the negative relationship found between age and STNFR1 concentrations. Previous
research indicates that STNFR1 may act as a natural inhibitor of TNF-α (Giai et al., 2013; Van
Zee et al., 1992). Consistent with this, a recent study by Forti et al. (2017) found that 9 weeks of
resistance training resulted in significant increases in serum concentrations of STNFR1 in
healthy young adults. These authors concluded that increased levels of STNFR1 in response to
resistance training may be beneficial in preventing age-related low-grade inflammation (Forti et
al., 2017; Franceschi et al., 2007). Notwithstanding, future research should focus on clarifying
the role of STNFRs as either beneficial or detrimental for health. Future research should also
compare circulating levels of TNF-α and STNFRs between sedentary and recreationally trained
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individuals to determine the role of training status and the effect of resistance training on these
markers.
No significant time x group interactions were observed between YA and MA for PTQ.
Since no significant difference was observed between the total work done during the damaging
protocol, it appears that the ability to recover PTQ following muscle damage does not
significantly decrease from young to middle age when individuals are recreationally trained.
While no differences in PTQ were observed between the two groups at any time-point, the YA
group showed a significantly higher mTQ at BL compared to the MA group. This finding
indicates a decreased ability to generate torque throughout the entire range of motion of the knee
extension with age. Both groups exhibited declines in mTQ at IP. mTQ in the YA group
remained significantly decreased at 120P and 48H while mTQ in the MA group was only
significantly decreased at 24H. The lower mTQ exhibited by MA at BL may account for the
quicker recovery of mTQ when compared to YA. When covaried for BL difference, no time x
group interaction is observed (data not shown).
No significant group x time interaction was observed for PP or mP. This finding indicates
that middle-aged males may be able to maintain muscle power if they meet the ACSM guidelines
for physical activity (Garber et al., 2011). Consistent with this, a recent meta-analysis found that
resistance training is an efficient strategy for improving lower body power in adults 50 years or
older (Straight, Lindheimer, Brady, Dishman, & Evans, 2016). When collapsed across groups,
PP was significantly decreased at IP relative to BL with no significant differences at any other
time point. A significant decrease in mP was also observed at IP and 120P relative to BL. The
exercise stimulus provided in the present study appeared to result in a decline in both peak power
and mean power; however, these values returned to BL values after 120 minutes and 24 hours,
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respectively. Future research comparing recovery of performance following muscle damage
between middle-aged and young age males may benefit from including sedentary counterparts in
order to determine the effect of training status on power recovery.
Previous research indicates that individuals tend to lose muscle mass at a rate of 1-2% per
year beginning as early as middle age (Buford et al., 2010; Lauretani et al., 2003) Therefore, we
anticipated that middle-aged males would have smaller muscle mass and lower muscle quality
when compared to young males However, no significant group differences were observed for
CSA, MT, or EI of the rectus femoris at BL. Previous research evaluating the effects of
resistance training on muscle CSA in middle-aged and older people demonstrated significant
increases in the CSA of the leg extensors after a 6-month training protocol (Hakkinen et al.,
1998). Since the middle-aged males recruited in the current study were recreationally trained, it
is possible that the age-related decline in muscle size and quality is delayed through the use of
recreational exercise including resistance training. Nonetheless, a positive correlation was
observed between age and EI of the RF. Additionally, a negative relationship was observed
between age and BL values of PTQ and mTQ. These findings are consistent with previous
research by Fukumoto et al. (2012), who found that muscle quality of the quadriceps assessed
from EI is positively correlated with age and negatively correlated with muscle strength in
middle-aged and elderly persons. Taken together, our findings indicate that muscle quality may
begin to decline as early as middle age and may serve as a possible reason behind the lower mTQ
observed in MA compared to YA at BL.
Limitations
Circulating STNFRs exist as either free STNFRs or as STNFR/TNF-α complexes
(Aderka, 1996). One of the limitations of the present study was that the assays used to measure
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STNFR1 and STNFR2 in serum were not specific to either bound or free form. Therefore, it is
unclear whether the binding of TNF-α to STNFRs in circulation interfered with the
quantification of total STNFRs via ELISA. It is conceivable that the serum concentrations of
STNFR1 and STNFR2 observed in the present study did not account for the STNFRs that were
bound to TNF-α. Moreover, the present study did not measure surface expression of TNFR1 or
TNFR2 on immune cells. Therefore, it is not clear whether the decreases observed in serum
concentrations of STNFR1 and STNFR2 were in fact a result of attenuated ectodomain shedding
from immune cells. Future studies may benefit from analyzing changes in circulating STNFRs in
conjunction with membrane TNFR receptor expressions. Lastly, the exercise intervention used in
the present study may not have been sufficiently vigorous to elicit an appreciable increase in
circulating TNF-α. A more intense resistance training protocol may be required to assess the
differences in the inflammatory response between young and middle-aged adults.
Conclusions
The present study compared the effects of an acute isokinetic muscle damaging
intervention on circulating levels of TNF-α and STNFRs between middle-aged and young age
males. Markers of muscle damage were similar between the two groups. No group differences
were observed in plasma TNF-α, STNFR1, or STNFR2 at BL. Therefore, our results indicate
that changes in circulating levels of TNF-α and STNFRs are not present at middle age but rather
may only be seen in older age (i.e. 65 years and older). However, a negative correlation was
observed between age and baseline values of STNFR1. Consequently, our results suggest that
natural inhibitors of TNF-α may decline as early as middle age. No group differences were
observed in the acute response of TNF-α and STNFRs to muscle damage. This finding indicates
that the pro-inflammatory response to muscle damage does not decline at middle age when
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individuals are recreationally trained. Aside from mTQ, no significant differences were observed
in lower body performance between YA and MA. Similarly, no significant differences in muscle
size or quality were observed between the two groups. Therefore, the age-related decline in
muscle size and function may not commence until later in life; or perhaps maintaining a
recreationally active lifestyle may delay these effects of aging.
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